A Micromethod for the Determination of the New Antiepileptic Drug Levetiracetam (ucb LO59) in Serum or Plasma by High Performance Liquid Chromatography
- 1 April 1996
- journal article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 18 (2), 154-157
- https://doi.org/10.1097/00007691-199604000-00008
Abstract
An isocratic high performance liquid chromatographic micromethod is described for the quantitation of levetiracetam (ucb LO59) in plasma or serum of patients. The chromatography is performed on a 250 × 4 mm I.D. LiChrospher 60 RP-select B, 5-μm column, eluted with an acetonitrile/50 mM phosphate buffer (15:85 vol/vol, pH 5.6) mobile phase, and levetiracetam detected using ultraviolet absorbance at 220 nm. The limit of quantitation was 5 μmol/L and the within-batch and between-batch coefficients of variation were <7%. No interference from commonly prescribed antiepileptic drugs (carbamazepine and its metabolite carbamazepine epoxide, ethosuximide, gabapentin, lamotrigine, phenobarbitone, phenytoin, primidone, valproic acid, and vigabatrin) was observed, and thus the method can be used to monitor levetiracetam in patients on polytherapy antiepileptic drug regimens.Keywords
This publication has 2 references indexed in Scilit:
- Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and ratsEuropean Journal of Pharmacology, 1993
- ucb L059, a novel anti-convulsant drug: pharmacological profile in animaisEuropean Journal of Pharmacology, 1992